Results 1 to 10 of about 3,917,698 (342)

Histopathologic Features of Maculopapular Drug Eruption

Dermatopathology, 2022
Background: Cutaneous adverse drug reaction (CADR) is common in both inpatient and outpatient clinical settings and has been associated with a large variety of medications.
Madison Ernst, Alessio Giubellino
doaj   +2 more sources

A Review of Fixed Drug Eruption with a Special Focus on Generalized Bullous Fixed Drug Eruption

Medicina, 2021
Fixed drug eruption (FDE) is a cutaneous adverse drug reaction characterized by the onset of rash at a fixed location on the body each time a specific medication is ingested. With each recurrence, the eruption can involve additional sites.
Hannah J. Anderson, Jason B. Lee
doaj   +2 more sources

Fixed drug eruption by etoricoxib confirmed by patch test* [PDF]

Anais Brasileiros de Dermatologia, 2016
Non-steroidal, anti-inflammatory drugs, followed by antibiotics, are the main causes of fixed drug eruption. They provoke one or several round erythematous or bullous lesions that recur in the same place after taking the causative medication.
Aline Soares de Sousa, J. Cardoso, M. Gouveia, A. Gameiro, V. Teixeira, M. Goncalo   +5 more
semanticscholar   +2 more sources

Risk of drug eruption associated with the use of tetracyclines, macrolides, and fluoroquinolones: real-world evidence from a pharmacovigilance study utilizing the FDA adverse event reporting system [PDF]

Saudi Pharmaceutical Journal
Recently, concerns regarding the risk of drug eruption associated with the use of tetracyclines were raised by the United States Food and Drug Administration (U.S. FDA). Therefore, it is necessary to reevaluate this risk. This study aimed to quantify the
Thamir M. Alshammari
doaj   +2 more sources

Grover’s-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy [PDF]

Journal of Immunotherapy for Cancer, 2016
BackgroundDermatologic toxicity is an important adverse effect of immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death 1 receptor (PD-1) or PD ligand 1 (PD-L1).
V. Koelzer, T. Buser, N. Willi, S. Rothschild, A. Wicki, P. Schiller, G. Cathomas, A. Zippelius, K. Mertz   +8 more
semanticscholar   +2 more sources

Fenofibrate-Induced Lichenoid Drug Eruption: A Rare Culprit

Case Reports in Dermatology, 2017
A lichenoid drug eruption is a rare side effect which can occur following the administration of several different medications. Here we describe a unique case of fenofibrate as the causative agent of a lichenoid drug eruption.
Fayeza Mohammed, Laura L. Wally, Jeffrey E. Karaban, Vijaya B. Reddy, Yongsuk Lertratanakul   +4 more
doaj   +2 more sources

Clinical Features and Drug Characteristics of Patients with Generalized Fixed Drug Eruption in the West of Iran (2005–2014)

Dermatology Research and Practice, 2015
Background. Generalized fixed drug eruption is a specific variant of fixed drug eruption with multifocal lesions. Diagnosis of this drug reaction is straightforward, but occasionally recognition of the causative drug is not possible. This study was aimed
Hossein Kavoussi, Mansour Rezaei, Katayoun Derakhshandeh, Alireza Moradi, Ali Ebrahimi, Harif Rashidian, Reza Kavoussi   +6 more
doaj   +2 more sources

Tenofovir induced lichenoid drug eruption

Avicenna Journal of Medicine, 2015
Cutaneous adverse reactions are a common complication of anti-retroviral therapy. Tenofovir is a newer anti-retroviral drug belonging to the nucleotide reverse transcriptase inhibitor group.
Mrinal Gupta, Heena Gupta, Anish Gupta
doaj   +2 more sources

Drug Eruptions [PDF]

BMJ, 1951
G. H. Percival
  +6 more sources

Unique skin manifestations of COVID-19: Is drug eruption specific to COVID-19? [PDF]

Journal of dermatological science (Amsterdam), 2020
T. Sakaida, I. Tanimoto, A. Matsubara, Motoki Nakamura, A. Morita   +4 more
semanticscholar   +2 more sources